Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer.

PharmacoEconomics - 1 Dec 2014

Alberts Steven R, Yu Tiffany M, Behrens Robert J, Renfro Lindsay A, Srivastava Geetika, Soori Gamini S, Dakhil Shaker R, Mowat Rex B, Kuebler John P, Kim George P, Mazurczak Miroslaw A, Hornberger John

Abstract excerpt

BACKGROUND: Prior economic analysis that compared the 12-gene assay to published patterns of care predicted the assay would improve outcomes while lowering medical costs for stage II, T3, mismatch-repair-proficient (MMR-P) colon cancer patients. This study assessed the validity of those findings with real-world adjuvant chemotherapy (aCT) recommendations from the US third-party payer perspective. METHODS: Costs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Drug Costs

Share to Genetic Testing

Share to Health Care Costs

Share to Neoplasm Recurrence, Local

Share to Quality-Adjusted Life Years

Source

Open in PubMed Open full text

Identifiers

PMID: 25154747
DOI: 10.1007/s40273-014-0207-1
PMCID: PMC4244576

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer.PMID 25154747Read ↗

Costs and effectiveness of genomic testing in the management of colorectal cancer.Semantic proximity Read ↗

12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.Semantic proximity Read ↗

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.Semantic proximity Read ↗

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.Semantic proximity Read ↗

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.Semantic proximity Read ↗

Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon CancerSemantic proximity Read ↗

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.Semantic proximity Read ↗

Assessment of Treatment Cost-effectiveness Using a Colorectal Cancer Mutation Profile.Semantic proximity Read ↗

Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.Semantic proximity Read ↗

Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.Semantic proximity Read ↗

Artificial Intelligence Can Cut Costs While Maintaining Accuracy in Colorectal Cancer GenotypingSemantic proximity Read ↗

Young-Onset Colon Cancer and Recurrence Risk by Gene Expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.